New insider activity at Adverum Biotechnologies ( (ADVM) ) has taken place on March 28, 2025.
Significant shareholder Braden Michael Leonard made notable transactions involving Adverum Biotechnologies stock. He purchased 20,407 shares valued at $102,647 and sold 16,593 shares for $85,951.
Recent Updates on ADVM stock
Adverum Biotechnologies has announced the initiation of the ARTEMIS Phase 3 study, which aims to evaluate the efficacy and safety of Ixo-vec as a one-time intravitreal injection for patients with neovascular age-related macular degeneration (wet AMD). This pivotal trial will compare a single administration of Ixo-vec to aflibercept administered every eight weeks in approximately 284 patients. The primary endpoint is the mean change from baseline in best corrected visual acuity at one year, with a non-inferiority margin of -4.5 letters. The study follows FDA guidance, requiring all patients to receive three loading doses of aflibercept before receiving Ixo-vec. ARTEMIS is the first of two planned Phase 3 trials, with details on the second study, AQUARIUS, to be announced later. This development could influence investor sentiment and stock price movements as it represents a significant step in Adverum’s clinical pipeline.
More about Adverum Biotechnologies
YTD Price Performance: 5.00%
Average Trading Volume: 175,293
Technical Sentiment Signal: Buy
Current Market Cap: $104.8M